NEWPORT PHARMACEUTICALS EXPANDING MAIL ORDER BUSINESS with the acquisition of mail service prescription drug provider Delivered Pharmacy Services from that firm's parent company, Lincoln National Administrative Services. Newport announced Aug. 14 that it will make the acquisition through its mail service prescription drug subsidiary, America's Pharmacy. Newport will pay $ 900,000 plus future payments based on performance of the Chicago-based firm. DPS, which has estimated annual revenues of $ 6.5 mil., provides drug plans to Lincoln National in the mid-sized group health market. Under the purchase agreement, America's Pharmacy will become sole provider of drug plans to Lincoln National's clients through 1994, Newport said. In April 1987, Newport entered the mail order field with the $ 12 mil. purchase of America's Pharmacy from Caremark. Since then, the Newport Beach, California-based firm has ended U.S./U.K. research and clinical trials on its lone pharmaceutical product, the immunomodulating agent Isoprinosine. FDA rejected Newport's NDA for Isoprinosine as a treatment for AIDS in 1985. Newport, which has retained U.S. marketing rights to the drug, also said Aug. 14 that it is "presently evaluating the data gathered by its Scandinavian licensee, AB Leo Pharmaceutical Products, in connection with a six-month, double-blind, placebo-controlled study examining the efficiency of . . . Isoprinosine in pre-AIDS patients." The company said it would again seek FDA marketing approval for the drug if its data analysis confirms Leo's preliminary finding that Isoprinosine helps to prevent the onset of AIDS in HIV-infected patients.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.
